Engineering and improving anti-CTLA-4 checkpoint inhibitors.
Galvez-Cancino F., Parkes EE., Withers DR., Melero I.
Next generation anti-CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumour-restricted activation. The goal is to achieve robust antitumour activity without inducing systemic immune-related toxicity.